Coronary Artery DiseasePhase 4PICIONCT04417634
RFR and FFR for the the Prediction of Post-PCI Results
A Phase 4 study testing RFR and FFR in people with Coronary Artery Disease, run by Johannes Gutenberg University Mainz at 1 site in Germany.
Trial summary
The aim of this study is to record hemodynamic pullback information using continuous resting full-cycle flow ratio (RFR) and fractional flow reserve (FFR) in patients with diffuse coronary artery disease. The capacity of the two indexes to predict the hemodynamic outcome after stenting will be compared. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Coronary Artery Disease
- What is being tested?
- RFR and FFR
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteGermany
- Study dates
- 10 May 2020to 10 Jun 2025
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients must meet ALL of the inclusion criteria:
- Clinical indication for elective percutaneous coronary intervention of a stenosis >40% and <90% with clinical indication to percutaneous intervention (PCI) requiring functional assessment. Note: the decision to perform functional assessment will have to be taken before, and independently of, the inclusion and randomization in the study.
- Documented heart team (when applicable, as per guidelines) decision for revascularization via PCI
- Patient ≥18 years old
Who cannot join
- Patients will be excluded if ANY of the exclusion criteria is met:
- Cardiogenic shock
- Any contraindication to PCI according to guidelines
- Presence of a coronary artery bypass grafting (CABG) in the territory under study
- Culprit vessels in patients with ST-segment elevation myocardial infarction (STEMI)
- TIMI (Thrombolysis in Myocardial Infarction) flow grade < 3
Show all 11Show fewer
- Lesion severity > 90% by visual assessment
- Presence of thrombus
- Participation in another randomized interventional study
- Patient unable to give informed consent
- Women of child-bearing potential or lactating
Trial locations and contacts
1 site in 1 country.
Germany1 site, 1 recruiting
- Recruiting
Center of Cardiology, Cardiology I, university hospital Mainz
Mainz, Rhineland-Palatinate, 55131
Tommaso Gori, Prof Dr, PhD, +49 (0) 6131 17 2729, tommaso.gori@unimedizin-mainz.de
Tommaso Gori, Prof Dr, PhD
About this study
Official title: Pullback wIth Resting Full-Cycle Flow ratIO or Fractional Flow Reserve for the Prediction of Post-PCI Hemodynamic Outcomes. A Study in Patients With Diffuse Coronary Artery Disease
The aim of this study is to record hemodynamic pullback information using continuous resting full-cycle flow ratio (RFR) and fractional flow reserve (FFR) in patients with diffuse coronary artery disease. The capacity of the two indexes to predict the hemodynamic outcome after stenting will be compared.
Goals of the study are:
- To study the accuracy of RFR/FFR gradients in predicting the change in whole-vessel RFR/FFR after PCI.
- To identify a threshold in the RFR/FFR gradient that is predictive of pathological RFR/FFR also after the PCI of the first lesion.
Read the detailed description
The study of the hemodynamic relevance of coronary stenoses is a well-validated method to identify coronary lesions to be treated. A number of studies show that FFR-guided PCI is superior to angiography guided PCI2-4. The achievement of maximal hyperemia is a prerequisite for FFR measurements. Hyperemia is usually achieved with the intravenous or intracoronary infusion of adenosine, which requires time and is potentially associated with discomfort for the patient. To avoid this, resting indexes have been developed. The instantaneous flow reserve (iFr) was the first of these indexes, and two large studies have shown that this parameter is non-inferior to FFR in terms of patient prognosis5. More recently, a number of other parameters have been developed, among which the RFR (resting flow ratio), which can be measured with the same intracoronary wire as the FFR and therefore requires no additional procedures. Studies show that these methods are equivalent6. The advantage of these resting indexes (which are all included in the most recent AHA/ACC guidelines7, 8), is that they do not require hyperemia. This might represent a particular advantage in the setting of tandem stenoses or diffuse disease. Since hyperemic flow in a vessel is limited by each one of the stenoses present in that vessel, each individual stenosis limits the capacity of FFR to assess the hemodynamic relevance of the other ones. In other words, invasive measurements of coronary hemodynamics using FFR in the setting of diffuse or tandem lesions are complicated by the fact that maximal hyperemia cannot be achieved, which limits the capacity of FFR to assess the hemodynamic relevance of individual focal stenoses. In this setting, the usual binary system (FFR < or > 0.80) cannot be easily applied.
This limitation is independent of the sequence of the stenoses: proximal lesions limit the reliability of FFR measurements in distal stenoses and vice versa (as long as no significant side branches are present between the two lesions). Since hyperemic flow declines significantly as soon as a 50% reduction in lumen diameter is present, even apparently non-relevant lesions may compromise any assessment based on hyperemia. This phenomenon, called hemodynamic interdependence of stenoses under conditions of hyperemia represents a significant limitation that applies to FFR but not to hyperemia-free indexes.
In order to address this issue in routine practice, FFR is measured first, then a pullback is performed and the lesion/segment where the pullback identifies the highest gradient is treated first. The removal of this stenosis increases maximal achievable hyperemic flow, thus increasing the significance of the remaining lesions. FFR is then measured again to test the hemodynamic significance of the other stenoses at a higher level of hyperemia. The capacity of FFR to predict whether removal of the first stenosis will be associated with the normalization of FFR is very limited, which requires that FFR be measured multiple times, prolonging the procedure and increasing the discomfort for the patient.
When studying coronary stenoses, the advantage of resting hemodynamic indexes is that non-critical stenoses (ie below 90%) do not modify resting blood flow. Because resting flow is more constant, and the effect of PCI is minimal, resting pressure changes measured across sequential lesions are likely to be more predictable.The hypothesis of the study is that, as compared to FFR, RFR will provide a better estimate of post-PCI hemodynamic outcomes.
- Conditions
- Coronary Artery Disease
- Being tested
- RFR, FFR
- Keywords
- stent, coronary stenosis, Angina
- Medical subject headings
- Coronary Artery Disease, Coronary Stenosis, Angina Pectoris
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RFRDiagnostic test
Measurement of resting flow ratio
FFRDiagnostic test
Measurement of fractional flow reserve
| Study group | Role | What they receive |
|---|---|---|
| RFR: resting full-cycle ratio | Experimental | RFR will be used to drive PCI Receives: Diagnostic Test: RFR |
| FFR: fractional flow reserve | Active comparator | FFR will be used to drive PCI Receives: Diagnostic Test: FFR |
What is being measured
The primary outcome is the main question the study is designed to answer.
Absolute difference between RFR observed and expected as compared to FFR observed versus expected.
Comparison of |RFRexp-RFRobs| vs. |FFRexp-FFRobs| (i.e., absolute differences between expected and observed final hemodynamic result) RFRexp and FFRexp are defined as (RFRbas plus RFRGrad) and (FFRbas plus FFRGrad)
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jun 2020
- Study start10 May 2020
- Primary completion10 Jun 2025 (estimated)
- Study completion10 Jun 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The study is a single-center, randomized superiority trial to compare two strategies for the assessment of the hemodynamic relevance of coronary lesions.
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Johannes Gutenberg University Mainz
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Tommaso Gori, Johannes Gutenberg University Mainz
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04417634
- Sponsor's protocol ID
- 2020-1
- Acronym
- PICIO
- Status last verified
- Sep 2023
- First submitted
- 1 Jun 2020
- Last updated
- 28 Sep 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pullback wIth Resting Full-Cycle Flow ratIO or Fractional Flow Reserve for the Prediction of Post-PCI Hemodynamic Outcomes. A Study in Patients With Diffuse Coronary Artery Disease
- ClinicalTrials.gov ID
- NCT04417634
- Acronym / sponsor ID
- PICIO / 2020-1
- Conditions
- Coronary Artery Disease
- Keywords
- stent, coronary stenosis, Angina
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Johannes Gutenberg University MainzUniversity, hospital or other
- Study start
- 10 May 2020 (actual)
- Primary completion
- 10 Jun 2025 (estimated)
- Study completion
- 10 Jun 2025 (estimated)
- First posted
- 5 Jun 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to record hemodynamic pullback information using continuous resting full-cycle flow ratio (RFR) and fractional flow reserve (FFR) in patients with diffuse coronary artery disease. The capacity of the two indexes to predict the hemodynamic outcome after stenting will be compared.
Goals of the study are:
- To study the accuracy of RFR/FFR gradients in predicting the change in whole-vessel RFR/FFR after PCI.
- To identify a threshold in the RFR/FFR gradient that is predictive of pathological RFR/FFR also after the PCI of the first lesion.
Detailed description
The study of the hemodynamic relevance of coronary stenoses is a well-validated method to identify coronary lesions to be treated. A number of studies show that FFR-guided PCI is superior to angiography guided PCI2-4. The achievement of maximal hyperemia is a prerequisite for FFR measurements. Hyperemia is usually achieved with the intravenous or intracoronary infusion of adenosine, which requires time and is potentially associated with discomfort for the patient. To avoid this, resting indexes have been developed. The instantaneous flow reserve (iFr) was the first of these indexes, and two large studies have shown that this parameter is non-inferior to FFR in terms of patient prognosis5. More recently, a number of other parameters have been developed, among which the RFR (resting flow ratio), which can be measured with the same intracoronary wire as the FFR and therefore requires no additional procedures. Studies show that these methods are equivalent6. The advantage of these resting indexes (which are all included in the most recent AHA/ACC guidelines7, 8), is that they do not require hyperemia. This might represent a particular advantage in the setting of tandem stenoses or diffuse disease. Since hyperemic flow in a vessel is limited by each one of the stenoses present in that vessel, each individual stenosis limits the capacity of FFR to assess the hemodynamic relevance of the other ones. In other words, invasive measurements of coronary hemodynamics using FFR in the setting of diffuse or tandem lesions are complicated by the fact that maximal hyperemia cannot be achieved, which limits the capacity of FFR to assess the hemodynamic relevance of individual focal stenoses. In this setting, the usual binary system (FFR < or > 0.80) cannot be easily applied.
This limitation is independent of the sequence of the stenoses: proximal lesions limit the reliability of FFR measurements in distal stenoses and vice versa (as long as no significant side branches are present between the two lesions). Since hyperemic flow declines significantly as soon as a 50% reduction in lumen diameter is present, even apparently non-relevant lesions may compromise any assessment based on hyperemia. This phenomenon, called hemodynamic interdependence of stenoses under conditions of hyperemia represents a significant limitation that applies to FFR but not to hyperemia-free indexes.
In order to address this issue in routine practice, FFR is measured first, then a pullback is performed and the lesion/segment where the pullback identifies the highest gradient is treated first. The removal of this stenosis increases maximal achievable hyperemic flow, thus increasing the significance of the remaining lesions. FFR is then measured again to test the hemodynamic significance of the other stenoses at a higher level of hyperemia. The capacity of FFR to predict whether removal of the first stenosis will be associated with the normalization of FFR is very limited, which requires that FFR be measured multiple times, prolonging the procedure and increasing the discomfort for the patient.
When studying coronary stenoses, the advantage of resting hemodynamic indexes is that non-critical stenoses (ie below 90%) do not modify resting blood flow. Because resting flow is more constant, and the effect of PCI is minimal, resting pressure changes measured across sequential lesions are likely to be more predictable.The hypothesis of the study is that, as compared to FFR, RFR will provide a better estimate of post-PCI hemodynamic outcomes.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- The study is a single-center, randomized superiority trial to compare two strategies for the assessment of the hemodynamic relevance of coronary lesions.
| Arm | Type | Receives |
|---|---|---|
| RFR: resting full-cycle ratio | Experimental | Diagnostic Test: RFRRFR will be used to drive PCI |
| FFR: fractional flow reserve | Active comparator | Diagnostic Test: FFRFFR will be used to drive PCI |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patients must meet ALL of the inclusion criteria:
Key exclusion criteria (11 listed)
- Patients will be excluded if ANY of the exclusion criteria is met:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RFRMeasurement of resting flow ratio | Diagnostic test | RFR: resting full-cycle ratio |
| FFRMeasurement of fractional flow reserve | Diagnostic test | FFR: fractional flow reserve |
Primary outcome
Absolute difference between RFR observed and expected as compared to FFR observed versus expected.
Time frame: 1 day
Comparison of |RFRexp-RFRobs| vs. |FFRexp-FFRobs| (i.e., absolute differences between expected and observed final hemodynamic result) RFRexp and FFRexp are defined as (RFRbas plus RFRGrad) and (FFRbas plus FFRGrad)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Sep 2023.
- Individual participant dataSharing planned: No
Related trials for Coronary Artery Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing RFR and FFR in people with Coronary Artery Disease, run by Johannes Gutenberg University Mainz at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 28 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Tommaso Gori (+491721052846, tomgori@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Absolute difference between RFR observed and expected as compared to FFR observed versus expected. (time frame: 1 day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2023.